171 related articles for article (PubMed ID: 10081493)
21. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
Hatakeyama S; Summermatter S; Jourdain M; Melly S; Minetti GC; Lach-Trifilieff E
Skelet Muscle; 2016; 6():26. PubMed ID: 27462398
[TBL] [Abstract][Full Text] [Related]
22. Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice.
Nai YJ; Jiang ZW; Wang ZM; Li N; Li JS
JPEN J Parenter Enteral Nutr; 2007; 31(1):18-25. PubMed ID: 17202436
[TBL] [Abstract][Full Text] [Related]
23. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice.
van Norren K; Kegler D; Argilés JM; Luiking Y; Gorselink M; Laviano A; Arts K; Faber J; Jansen H; van der Beek EM; van Helvoort A
Br J Cancer; 2009 Mar; 100(5):713-22. PubMed ID: 19259092
[TBL] [Abstract][Full Text] [Related]
24. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
Kanzaki M; Soda K; Gin PT; Kai T; Konishi F; Kawakami M
Cytokine; 2005 Dec; 32(5):234-9. PubMed ID: 16338141
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
26. Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice.
Salazar-Degracia A; Granado-Martínez P; Millán-Sánchez A; Tang J; Pons-Carreto A; Barreiro E
J Cell Physiol; 2019 Aug; 234(10):18041-18052. PubMed ID: 30851071
[TBL] [Abstract][Full Text] [Related]
27. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6.
Soda K; Kawakami M; Kashii A; Miyata M
Int J Cancer; 1995 Jul; 62(3):332-6. PubMed ID: 7628876
[TBL] [Abstract][Full Text] [Related]
28. MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia.
Zhang L; Tang H; Kou Y; Li R; Zheng Y; Wang Q; Zhou X; Jin L
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1105-15. PubMed ID: 23535871
[TBL] [Abstract][Full Text] [Related]
29. Changes in activity of lipoprotein lipase, plasma free fatty acids and triglycerides with weight loss in a cachexia model.
Briddon S; Beck SA; Tisdale MJ
Cancer Lett; 1991 Apr; 57(1):49-53. PubMed ID: 2025878
[TBL] [Abstract][Full Text] [Related]
30. [Cytokines in experimental cancer cachexia].
Niu Q; Li T; Liu A
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):382-4. PubMed ID: 11810767
[TBL] [Abstract][Full Text] [Related]
31. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Guo D; Wang C; Wang Q; Qiao Z; Tang H
Oncotarget; 2017 Jun; 8(24):39640-39648. PubMed ID: 28489606
[TBL] [Abstract][Full Text] [Related]
32. Glucocorticoid blockade does not abrogate tumor-induced cachexia.
Rivadeneira DE; Naama HA; McCarter MD; Fujita J; Evoy D; Mackrell P; Daly JM
Nutr Cancer; 1999; 35(2):202-6. PubMed ID: 10693176
[TBL] [Abstract][Full Text] [Related]
33. Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia.
Soda K; Kawakami M; Kashii A; Miyata M
Jpn J Cancer Res; 1994 Nov; 85(11):1124-30. PubMed ID: 7829397
[TBL] [Abstract][Full Text] [Related]
34. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma.
Iizuka N; Hazama S; Yoshimura K; Yoshino S; Tangoku A; Miyamoto K; Okita K; Oka M
Int J Cancer; 2002 May; 99(2):286-91. PubMed ID: 11979446
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Chacon-Cabrera A; Fermoselle C; Urtreger AJ; Mateu-Jimenez M; Diament MJ; de Kier Joffé ED; Sandri M; Barreiro E
J Cell Physiol; 2014 Nov; 229(11):1660-72. PubMed ID: 24615622
[TBL] [Abstract][Full Text] [Related]
36. Role of PARP activity in lung cancer-induced cachexia: Effects on muscle oxidative stress, proteolysis, anabolic markers, and phenotype.
Chacon-Cabrera A; Mateu-Jimenez M; Langohr K; Fermoselle C; García-Arumí E; Andreu AL; Yelamos J; Barreiro E
J Cell Physiol; 2017 Dec; 232(12):3744-3761. PubMed ID: 28177129
[TBL] [Abstract][Full Text] [Related]
37. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
38. 5'-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice.
Eda H; Tanaka Y; Ishitsuka H
Cancer Chemother Pharmacol; 1991; 29(1):1-6. PubMed ID: 1835906
[TBL] [Abstract][Full Text] [Related]
39. Muscle oxidative capacity during IL-6-dependent cancer cachexia.
White JP; Baltgalvis KA; Puppa MJ; Sato S; Baynes JW; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R201-11. PubMed ID: 21148472
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic activity of FK973 against human oral and breast cancer cells.
Wu JZ; Adachi I; Watanabe T
Chin Med J (Engl); 1991 Oct; 104(10):834-7. PubMed ID: 1661225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
